MS Patients' switch to ozanimod under the microscope
NCT ID NCT05658601
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 104 people with relapsing-remitting multiple sclerosis (RRMS) who switched their disease-modifying therapy to ozanimod. Researchers tracked why they switched (e.g., lack of effectiveness, side effects) and how the switch was done. The goal was to understand real-world use, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Isernia, 86077, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentle electric zap to the brain restore memory in MS?
- Brain scans may reveal how MS drug affects mental fatigue
- Brain scans could reveal which MS drugs fight mental exhaustion
- Brain shrinkage as a crystal ball for MS progression?
- Can a Once-a-Month shot tame MS relapses?
- Can MS treatments protect the mind as well as the body?